Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC

Life science deal-making declined by volume during the first quarter, but aggregate value was up. Looking ahead, PwC sees an ideal environment for major deals – if something like Takeda/Shire sparks a trend.

Rocket takes off from the hand of the businessman. Concept of start up.

By volume, life sciences deal-making declined during the first quarter of 2018, although four fairly large deals meant that the aggregate value of such deals rose compared to the fourth quarter, PwC’s deal practice notes in a new report. But the group thinks completion of one big transaction could open the floodgates, so to speak.

There has been a lot of speculation about an increase in deals with the US corporate tax reform that passed...

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.